METASTATIC UROTHELIAL CARCINOMA

This early-phase trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 65 adults wi…

This study tests whether combining two drugs—pemetrexed and avelumab—can shrink or control advanced bladder cancer that has a specific genetic marker (MTAP deficiency) and has spread. About 18 adults who have already had chemotherapy will receive the combination. The goal is to s…

This study tests a new three-drug combination for people with advanced bladder cancer that has spread or cannot be removed by surgery. The goal is to find the safest dose and see if the combination shrinks tumors. About 57 participants will receive the targeted drug ixazomib plus…

This study tests whether adding new drugs (favezelimab or vibostolimab) to the standard combination of pembrolizumab and enfortumab vedotin can better shrink tumors in people with advanced bladder cancer that has not been treated before. About 390 participants will receive one of…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific gene change (FGFR3). The goal is to find a safe dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to standard tre…

This early-stage trial tests a combination of two drugs—erdafitinib and enfortumab vedotin—for people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. The goal is to find the safest and most effective dose and see if the combo can shrink or stab…

This study looks at whether people with advanced bladder cancer can stop taking immunotherapy drugs (like pembrolizumab or nivolumab) after about a year instead of continuing indefinitely. The goal is to see if stopping early leads to similar survival rates while reducing side ef…

This study tests a new combination of drugs (MK-2870 plus enfortumab vedotin, with or without pembrolizumab) in people with advanced bladder cancer that has spread. The goal is to see if the combination is safe and shrinks tumors. About 38 adults will take part in two phases: fir…

This early-phase trial tests the safety and best dose of sonidegib combined with the immunotherapy pembrolizumab in people with advanced solid tumors that have spread. The goal is to see if this drug pair can shrink tumors or slow their growth. About 36 adults with cancers like m…

This study tests a drug called sapanisertib in people with advanced bladder cancer that has a specific change in the TSC1 or TSC2 gene. The drug works by blocking a protein that helps cancer cells grow. The goal is to see if the drug can shrink tumors and how well people tolerate…

This study tests whether giving the drug enfortumab vedotin less often can still control advanced bladder cancer while reducing side effects. About 60 adults with cancer that has spread will receive the drug alone or with pembrolizumab. The goal is to see if a de-escalated schedu…

This early-stage trial was designed to test a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) in people with advanced bladder cancer that had not been treated before. The goal was to see if the combination was safe and could help control the cancer. Howe…

This early-phase trial is testing a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus a targeted drug (belinostat) in people with advanced bladder cancer that has spread or cannot be removed surgically. The main goal is to find the safest dose and understa…

This study tests a combination of three drugs (ipilimumab, nivolumab, and sacituzumab govitecan) as a first treatment for advanced bladder cancer in people who cannot receive standard cisplatin chemotherapy. The goal is to see if the combo can shrink or control tumors. About 46 a…

This study tests whether adding eribulin to standard chemotherapy helps people with advanced bladder cancer live longer. It is for patients whose cancer has spread and no longer responds to immunotherapy. About 184 adults will receive either the new drug combo or the usual chemo …

This early-phase study tests a combination of two drugs—tazemetostat and pembrolizumab—in people with advanced bladder cancer that has spread. Tazemetostat blocks certain enzymes that help cancer grow, while pembrolizumab helps the immune system fight the cancer. The goal is to f…

This study tests a drug called ceralasertib, either alone or combined with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, endometrial, and prostate cancers. The goal is to see if these combinations can shrink tumors or slow their gr…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study tests adding propranolol, a blood pressure drug, to standard immunotherapy for people with advanced bladder cancer that has spread. The goal is to see if the combination is safe and helps control the cancer. Only 6 adults took part, and the study is no longer recruitin…

This study looks at whether a blood test (ctDNA) can better detect certain genetic changes (FGFR) in metastatic bladder cancer compared to the usual tissue biopsy. About 260 patients will have both tests to see if the blood test identifies more people who could benefit from the d…

This study looks at whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well the immunotherapy drug nivolumab works in people with advanced bladder cancer that has spread. About 6 participants with these gene changes will receive nivolum…